Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02892409
Other study ID # TAK-438_115
Secondary ID U1111-1179-58160
Status Completed
Phase Phase 1
First received
Last updated
Start date September 5, 2016
Est. completion date May 11, 2017

Study information

Verified date June 2018
Source Takeda
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the safety, tolerability, and pharmacokinetics (PK) of quadruple therapy with bismuth, clarithromycin, amoxicillin, and TAK-438 versus quadruple therapy with bismuth, clarithromycin, amoxicillin, and lansoprazole.


Description:

This is a phase 1, double-blind, parallel group study in participants with Helicobacter pylori (HP positive) who are, additionally, cytochrome P-450 (CYP)2C19 extensive metabolizers (EM) to evaluate the safety, tolerability and pharmacokinetics (PK) of a quadruple therapy with bismuth, clarithromycin, amoxicillin, and TAK-438 versus quadruple therapy with bismuth, clarithromycin, amoxicillin, and lansoprazole. The study will enroll 30 participants.

The treatment phase consists of quadruple therapy twice daily (BID) with tripotassium bismuth dicitrate (600 mg), clarithromycin (500 mg), amoxicillin (1000 mg), and TAK-438 (20 mg) (Group B) or quadruple therapy BID with tripotassium bismuth dicitrate (600 mg), clarithromycin (500 mg), amoxicillin (1000 mg),and lansoprazole (30 mg) (Group A) from Days 1 to 14. Participants will be discharged on Day 15 after final PK blood samples are collected and all procedures performed.

This single-center will be conducted in Korea. Participants will remain confined to the study site from check-in (Day -1) through Day 15 and will followed up through call on Day 17 and return on Day 42 for a follow-up assessment.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date May 11, 2017
Est. primary completion date April 17, 2017
Accepts healthy volunteers No
Gender All
Age group 19 Years to 60 Years
Eligibility Inclusion Criteria:

1. HP positive participants.

2. Has body mass index between greater than (>) 18 and less than equal to (<=) 30 kilogram per square meter (kg/m^2) and weighs greater than equal to (>=) 50 kilogram (kg).

3. Is willing to abstain from strenuous exercise from 72 hours before first dose (Day 1) until the Follow-up call on Day 17.

Exclusion Criteria:

1. Has a positive urine drug result for drugs of abuse at Screening or Check-in (Day -1).

2. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse (defined as regular consumption of 21 units or more units per week) at any time prior to the Screening Visit or is unwilling to agree to abstain from alcohol and drugs throughout the study (up to Day 17).

3. Has history of gastroesophageal reflux disease (GERD), symptomatic GERD, erosive esophagitis, duodenal ulcer, gastric ulcer, Barrett's esophagus, or Zollinger-Ellison syndrome.

4. Has undergone therapeutic upper gastrointestinal endoscopic therapy (example, endoscopic hemostasis or excision including biopsy) within 30 days prior to Screening.

5. Has undergone major surgical procedures within the past 1 month or are scheduled to undergo surgical procedures that may affect gastric acid secretion (example, abdominal surgery, vagotomy, or craniotomy).

6. Has a history of cancer, except basal cell carcinoma or Stage 1 squamous cell carcinoma of the skin that has been in remission for at least 5 years prior to Day 1.

7. Has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody/antigen at Screening.

8. Has used nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum) within 6 weeks prior to Check-in. Cotinine test is positive at Screening or Check-in.

9. Has poor peripheral venous access. Has donated or lost 450 milliliter (mL) or more of his blood volume (including plasmapheresis), or had a transfusion of any blood product within 90 days prior to Day 1.

10. Has abnormal Screening or Check-in laboratory values that suggest a clinically significant underlying disease or subject with the following laboratory abnormalities: alanine aminotransferase (ALT), aspartate aminotransferase (AST) or total bilirubin > the upper limit of normal (ULN).

11. Has reduced renal function assessed by having an estimated glomerular filtration rate <90 milliliter per min per 1.73 square meter (mL/min/1.73 m^2) (as estimated by Chronic Kidney Disease-Epidemology Collaboration) at Screening or Check-in.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Clarithromycin
Clarithromycin tablets
Amoxicillin
Amoxicillin capsules
Tripotassium bismuth dicitrate
Tripotassium bismuth dicitrate tablets
Lansoprazole
Lansoprazole capsules
TAK-438
TAK-438 tablets

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Takeda

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) Baseline up to Day 17
Primary Percentage of Participants Who Discontinue Due to an Adverse Event (AE) Baseline up to Day 17
Primary Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post-dose Baseline up Day 15
Primary Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post-dose Baseline up to Day 15
Primary Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at Least Once Post-dose Baseline up to Day 15
Primary Cmax: Maximum Observed Plasma Concentration for Bismuth Day 14 pre-dose and at multiple timepoints (up to 12 hours) post-dose
Primary AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Bismuth Day 14 pre-dose and at multiple timepoints (up to 12 hours) post-dose
Primary Aet: Amount of Drug Excreted in Urine During a Dosing Interval for Bismuth Day 14 pre-dose and at multiple timepoints (up to 12 hours) post-dose
See also
  Status Clinical Trial Phase
Completed NCT05073367 - A Study Reviewing Medical Records of Adults With Helicobacter Pylori Infections in China
Completed NCT00596401 - The Preventive Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer
Not yet recruiting NCT04101708 - A Comparison of High-dose Dual Therapy and Half-dose Clarithromycin-containing Bismuth Quadruple Therapy for H.P Eradication in Elderly Patients Phase 4
Recruiting NCT04029493 - The Situation of Re-infection of Helicobacter Pylori After Successful Eradication
Recruiting NCT04029415 - The Study of the Antimicrobial Resistance of Helicobacter Pylori in Shandong Province
Recruiting NCT04030715 - The Associations Between the Gastric Mucosal Pathology and the Eradication Rate of H.Pylori :A Multicenter Study N/A
Not yet recruiting NCT02933229 - The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study Phase 4
Not yet recruiting NCT02934048 - Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection Phase 4
Recruiting NCT05184491 - Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management Phase 4
Recruiting NCT05790525 - Effect of Oral Helicobacter Pylori Infection on the Efficacy of Gastroluminal Helicobacter Pylori Eradication Therapy Phase 4
Completed NCT05790512 - Association of Oral Helicobacter Pylori Infection With Gastric Helicobacter Pylori Infection
Recruiting NCT05276557 - PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study Phase 3
Recruiting NCT03177629 - H. Pylori Eradication for Moderate ITP Phase 3
Recruiting NCT05053945 - Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study
Recruiting NCT05449028 - Helicobacter Pylori Eradication Therapy in Portugal N/A
Recruiting NCT00306280 - Feasibility Study of Phototherapy System to Treat H Pylori N/A
Active, not recruiting NCT02675010 - Value of Additional Corpus Biopsy for Diagnosis of H Pylori in Atrophic Gastritis. Prospective Non-randomized Study N/A
Withdrawn NCT00467155 - Helicobacter in The Gambia (Part 2) N/A
Completed NCT03716622 - A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication Phase 4
Not yet recruiting NCT04937426 - Development of a Laboratory Test for the Detection of a Fluorescent-labeled Urease Inhibitor Marker Attached to Helicobacter Pylori N/A